Status:
RECRUITING
Clinical Pre-screening Protocol for Ovarian Cancer
Lead Sponsor:
Allarity Therapeutics
Collaborating Sponsors:
Amarex Clinical Research
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be lik...
Eligibility Criteria
Inclusion
- Patients with histological confirmed epithelia ovarian cancer
- Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.
- Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting
- FFPE tumor tissue available
Exclusion
- Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.
- Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator
Key Trial Info
Start Date :
April 11 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03877796
Start Date
April 11 2019
End Date
December 1 2026
Last Update
October 30 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
2
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73104
3
Swedish Center for Research and Innovation
Seattle, Washington, United States, 98122
4
Beatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom, G12 0YN